insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

BLPH · Bellerophon Therapeutics, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ3 '23Q2 '23Q1 '23Q4 '22Q3 '22Q2 '22Q1 '22Q4 '21Q3 '21Q2 '21
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$544.0K$2.90M$2.55M-$3.75M$4.49M$4.41M-$3.03M$3.24M
SG&A$1.63M$2.36M$1.61M-$1.37M$2.05M$1.23M-$1.77M$1.99M
Total Operating Expenses$2.17M$5.26M$4.16M-$5.12M$6.54M$5.64M-$4.80M$5.23M
D&A----------
Operating Income($2.17M)($5.26M)$1.48M-($5.12M)($6.54M)($5.64M)-($4.80M)($5.23M)
Interest Expense----------
Income Tax--($1.28M)--($2.42M)---($1.80M)
Net Income($1.92M)($5.14M)$2.82M-($5.07M)($4.11M)($5.64M)-($4.63M)($3.39M)
EPS - Basic($0.16)($0.42)$0.27-($0.53)($0.43)($0.59)-($0.49)($0.36)
EPS - Diluted($0.16)($0.42)$0.27-($0.53)($0.43)($0.59)-($0.49)($0.36)

Balance Sheet

Line itemQ3 '23Q2 '23Q1 '23Q4 '22Q3 '22Q2 '22Q1 '22Q4 '21Q3 '21Q2 '21
Cash & Equivalents$4.38M$10.57M$15.17M$6.92M$11.32M$16.33M$20.00M$24.74M$28.71M$34.30M
Accounts Receivable----------
Inventory----------
Accounts Payable$612.0K$1.89M$1.07M$1.23M$1.52M$2.01M$2.19M$1.19M$1.28M$2.48M
Current Assets$4.98M$11.24M$15.77M$7.56M$12.06M$16.99M$20.52M$25.46M$29.71M$35.29M
Total Assets$4.98M$11.24M$15.97M$7.93M$12.61M$17.73M$21.75M$26.88M$31.32M$37.08M
Current Liabilities$1.26M$5.62M-$5.40M$5.18M$5.45M$5.57M$5.05M$5.13M$6.23M
Long-term Debt----------
Total Liabilities$1.26M$5.62M$5.36M$5.40M$5.18M$5.45M$5.58M$5.26M$5.52M$6.98M
Stockholders' Equity$3.72M$5.62M$10.60M$2.53M$7.43M$12.28M$16.17M$21.62M$25.79M$30.10M
Retained Earnings($256.31M)($254.39M)($249.26M)($252.08M)($247.06M)($241.99M)($237.89M)($232.25M)($227.97M)($223.34M)

Cash Flow

Line itemQ3 '23Q2 '23Q1 '23Q4 '22Q3 '22Q2 '22Q1 '22Q4 '21Q3 '21Q2 '21
Operating Cash Flow--$3.27M---($4.74M)---
Investing Cash Flow----------
Financing Cash Flow--$0-------
CapEx----------
Free Cash Flow----------

Ratios

MetricQ3 '23Q2 '23Q1 '23Q4 '22Q3 '22Q2 '22Q1 '22Q4 '21Q3 '21Q2 '21
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate---82.7%-------
Return on assets-38.6%-45.7%17.7%--40.2%-23.2%-25.9%--14.8%-9.1%
Return on equity-51.6%-91.4%26.6%--68.2%-33.4%-34.9%--18.0%-11.3%
Return on invested capital----------
Liquidity
Current ratio3.962.00-1.402.333.123.695.045.805.67
Quick ratio3.962.00-1.402.333.123.695.045.805.67
Cash ratio3.491.88-1.282.193.003.594.905.605.51
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier1.342.001.513.131.701.441.341.241.211.23
Liabilities / Assets0.250.500.340.680.410.310.260.200.180.19
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)57.6%19.6%---6.5%-25.2%3.7%-41.9%9.3%
Net income growth (YoY)62.1%-25.2%---9.4%-21.1%-3.3%-41.6%11.3%
EPS growth (YoY)69.8%2.3%---8.2%-19.4%-1.7%-41.7%29.4%
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)-49.9%-54.2%-34.4%-88.3%-71.2%-59.2%-51.2%-43.5%-43.8%-43.6%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Bellerophon Therapeutics against the 5 most active filers in the same SIC group.